Introduction
Whether acquired through natural infection or vaccination with live attenuated influenza vaccine (LAIV), antibody-mediated protection at mucosal surfaces is thought to play a key role in preventing influenza infections 1 . In particular IgA at mucosal surfaces has been shown to play a role in reducing viral shedding 2 . To support the assessment of mucosal influenza vaccines in future clinical trials and studies of naturally-acquired mucosal immunity, standardized sample collection methods from nasal mucosal lining fluid (MLF) are required that acceptable to participants (especially young children) and collect consistent MLF volumes. Furthermore, the volume collected and concentration of influenza-specific antibodies should be sufficient to measure mucosal responses to all influenza strains included in the vaccine. These aspects are also dependent on the requirements, performance and sensitivity of the IgA assay used, which traditionally has been based on ELISA techniques.
We present the results of a pilot study assessing different methods for collecting nasal MLF to detect both total and influenza-specific IgA: (i) nasal wash, the method traditionally used for this purpose but challenging in young children and subject to erratic sample recovery (ii) flocked swabs and (iii) synthetic absorptive matrix (SAM) strips. We also compare a highly sensitive ELISA modified from previous studies 2, 3 and a novel protein microarray requiring minimal sample volume, adapted to measure influenza-specific IgA 4 .
Materials and Methods

Subjects, vaccination and mucosal lining fluid sampling methods
Thirteen healthy adult volunteers (age 25 -44 years, 8 male, 5 female) were recruited following written informed consent at the Clinical Research Facility, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Ethical approval was granted by the Leeds East National Research Ethics Service Committee. Nasal MLF was sampled immediately prior to vaccination with 2015/16 seasonal tetravalent LAIV (Fluenz Tetra, Astra Zeneca, UK) and 28 days later via three methods: (i) Flocked swabs (Copan Diagnostics Inc., Murrieta, CA, USA) (ii) SAM strips (Hunt Diagnostics, UK) and (iii) Nasal washes using the Naclerio method 5 . A day 28 post-vaccine timepoint was chosen due to prior studies showing a mucosal IgA response to LAIV in both children and adults at approximately 1 month after vaccination 6, 7 . Subjects were administered tetravalent LAIV into the nasal cavity (0.1ml per nostril). This vaccine contained the haemagglutinin (HA) and neuraminidase (NA) from a A/California/7/2009 (H1N1) pdm09-like strain (A/Bolivia/559/2013) and A/Switzerland/9715293/2013 (H3N2) as the two influenza A antigens on the A/Ann Arbor/6/60 attenuated backbone.
Sample collection and processing
All samples were collected by one operator, processed within 3 hours of collection and stored at -70˚C. The order of sample collection (nasal swab, strip, wash) was kept consistent at all visits with approximately 15 minute intervals in between. Sample processing was undertaken according to already established protocols using these methods. Nasal swabs were inserted into the nasal cavity and repeatedly rotated 360˚ for approximately 5 seconds. Secretions were eluted by centrifugation at 4˚C through a Costar® spin-X® tube (0.22µm pore size, Sigma, UK) pre-incubated with 300µl of extraction buffer (EB: phosphate buffered saline (PBS) containing 0.02% sodium azide and 0.25M NaCl). Repeat centrifugation with a further 300µl of EB was performed. One swab from each nostril was obtained and eluted material pooled. A single SAM strip was inserted into a patent nostril according to the manufacturer's instructions for 60 seconds. Material was eluted in 300µl of EB by centrifugation as detailed above. Material from one nostril at day 0 and both nostrils (processed separately) at day 28 were obtained. Nasal washes were obtained using the Naclerio method 5 , by instilling 10ml of sterile 0.9% NaCl into each nostril in turn and asking the subject to expel forcefully into a sterile container. Collected material was centrifuged at 4˚C
and supernatant stored at -70˚C.
2.3
Enzyme-linked Immunosorbent Assays (ELISA)
Total IgA ELISA
An ELISA was modified from previously described methods used to detect anti-HIV-1 antibodies 8, 9 . ELISA plates (medium binding, Greiner Bio-One) were coated 1:1 with anti-Human kappa and quantification using an IgA standard curve was performed as described above.
Haemagglutinin Microarray to detect anti-influenza IgA antibodies
A previously described HA microarray designed to profile anti-influenza IgG antibodies in human Mean spot fluorescence foreground intensity was determined by using ScanArray® Express software (PerkinElmer, USA).
Influenza microneutralization assays
MLF from SAM strip-eluted material was tested by standard methods using a microneutralization (MN) assay as described previously 10 , with egg-cultured A/California/7/2009 H1N1pdm09 virus.
Briefly, samples were heat inactivated for 30 min at 56˚C and 2-fold serial dilutions from 1:10 to 1:320 in 50µl volume of PBS (in duplicate) were mixed with an equal volume of influenza virus previously titrated on Madin-Darby canine kidney (MDCK) cells. After a 1-hour incubation at room temperature, 100µl of MDCK cells at 5 x 10 5 /ml was added to each well and plates incubated for 16 -18 hours at 37 ˚C. Monolayers were washed and fixed in cold methanol/H 2 0 2 (0.6%) for 30 minutes. The presence of influenza nucleoprotein (NP) was detected by ELISA with a monoclonal antibody to the influenza A NP as described previously 11, 12 . MN titres were calculated as the MLF dilution at which 50% reduction in the virus-infected to uninfected optical density (OD) ratio was seen.
Statistical analyses
Based on a previous study comparing allergen-specific IgA detection in SAM strips and nasal washes 13 , we calculated that 5 participants would be sufficient to detect a 2-fold difference in anti-influenza IgA levels at day 28 post-LAIV between these two methods (power 90%, alpha 0.01). To account for a proportion of subjects without detectable IgA and potential dropouts, we aimed to recruit 10 -15 participants. All statistical analyses were performed using GraphPad respectively. Significant differences between sampling methods are shown in Figure 1a and 1b.
Total IgA values for each subject were more consistent across visits in flocked swab and SAM strip samples than nasal wash samples, with a significant correlation seen between day 0 and day 28 total IgA quantities for each subject in samples collected by swab and strip (Figure 1c -e ). Finally, total IgA quantities in samples collected from left and right nares using SAM strips at day 28 were compared and no significant difference found (median 335.0 vs 228.7µg/ml, p = 0.45), with a good correlation between the two (r s 0.736, p = 0.002)(data not shown).
Standardization of H1pdm09-specific IgA to total IgA results in comparable values between sampling methods
To account for variability in the volume of MLF collected across subjects and visits, H1pdm09 HAspecific IgA quantities were expressed as a percentage of total IgA. These were more comparable between nasal swabs and SAM strips than raw values at both day 0 and day 28 ( Fig 2) . The percentage H1pdm09 HA-specific IgA in nasal washes was, however, significantly higher than in flocked swabs at day 28. This may reflect the trend towards a greater yield of total IgA in swabs compared to washes (Fig 1a) . A good correlation is seen between percentage H1pdm09 HAspecific/total IgA values between methods in each subject (Fig 3) , with the most comparable being flocked swab and SAM strips, again suggesting that these are more comparable and consistent methods of MLF collection.
Comparison of haemagglutinin microarray and ELISA to detect anti-influenza IgA and the mucosal response to LAIV
A disadvantage of ELISA is the sample volume required per antigen tested, making it challenging to measure antibodies to all antigens included in seasonal influenza vaccines. HA microarray 4 is able to reliably detect anti-influenza IgG in very small quantities of serum (10µl), so we tested the ability of this assay to detect anti-influenza IgA in MLF. Due to sample volume availability, H3 HAspecific IgA ELISAs were only performed on flocked swab (and not SAM strip) material. A good correlation was seen between both H1pdm09 HA and H3 HA influenza-specific IgA levels (fluorescence units) in the HA microarray and IgA quantified by ELISA in ng/ml (Fig 4) . This was in spite of a mismatch in H3 HA antigen in the microarray slides prepared for a previous study (A/Brisbane/10/2007) and that of the vaccine antigen (A/Switzerland/9715293/2013).
To assess the mucosal IgA response to LAIV, the fold difference was calculated between day 28 and day 0 samples in influenza-specific IgA measured by ELISA and HA microarray for each subject (in each case normalized by the total IgA quantity). A ≥2-fold increase was considered a significant response as defined in a previous LAIV study 6 . This was undertaken for swab samples in the 10 subjects for whom comparable H1pdm09 and H3-specific data were available (Supplementary Table 1 ). No subject showed a significant increase in H1pdm09 HA-specific IgA post-vaccine using ELISA-measured data, with one subject showing an H3-specific IgA response.
In contrast, three subjects showed an H1-specific IgA response and three subjects an H3-specific IgA response to LAIV using HA microarray measured data (with two subjects showing a response to both antigens).
Low titre influenza microneutralization activity is detectable in nasal mucosal lining fluid
To evaluate a more functional readout of anti-influenza activity in MLF, available SAM stripcollected material (as those with the greatest antibody yield) were tested in a standard influenza microneutralization (MN) assay. While 11/25 of samples tested showed detectable titres against A/California/7/2009 H1N1pdm09 virus, these were all low titre (1:10 -1:24). A weak but significant correlation was observed between the reciprocal MN titre and H1pdm09 HA-specific IgA value quantified by ELISA (Fig 5a) . Interestingly, a greater correlation was observed between reciprocal MN titres and H1pdm09 HA-specific IgA levels (fluorescence units) detected in the HA microarray (Fig 5b) .
Discussion
Reliable, high-yield, participant-acceptable methods to assess mucosal anti-influenza humoral activity are vital in studies of both natural infection and vaccine-induced immunity. We provide (to our knowledge for the first time) a direct comparison of nasal washes with flocked swabs and SAM strips to collect MLF and measure influenza-specific IgA responses, with the latter two representing techniques with greater convenience for both the investigator and study participant.
We demonstrate that the yield of total and influenza-specific IgA is significantly higher in SAM strips compared to flocked swabs or nasal washes. This is in keeping with previous reports of greater cytokine 13, 14 and allergen-specific antibody 13 We also sought to measure functional responses in SAM strip samples by using a standard influenza MN assay. Although neutralizing antibody was detected in 44% of samples tested, titres were low, suggesting that this is not a suitable method to assess functional responses in nasal MLF despite the higher antibody yield in SAM strip samples. We found only a weak correlation between ELISA-quantified influenza-specific IgA and MN titres. While this could be due to the lack of precision in MN titres at such a restricted range, it could also be explained by varying degrees of functional activity in binding IgA antibodies, which may limit the spread of budding virus from the cell, rather than classical entry inhibiting neutralization 16 . IgG, unmeasured in this study, may make a more significant contribution to neutralization measured by the in vitro assay used.
Interestingly, the correlation between MN activity and H1pdm09 influenza-specific IgA detected in the microarray was greater. Whether microarray-detected IgA levels are a better surrogate marker of neutralizing activity in nasal MLF than ELISA-quantified values requires further investigation. There remains a need to combine a functional assay with a convenient MLF sampling method.
Finally, although the main purpose of the study was to evaluate sampling methods and antiinfluenza IgA detection assays, we assessed the mucosal IgA response to the H1N1pdm09 and H3N2 components in tetravalent LAIV in the limited sample of adults in the study. Using a ≥2-fold increase from baseline post-LAIV as a significant response 6 , none of ten subjects showed a H1N1pdm09-specific response, with one subject showing a H3N2-specific response in ELISAmeasured influenza-specific IgA data. This is consistent with previous reports of lower LAIV efficacy in adults compared to children 17 and poor antibody responses to H1N1pdm09 compared to H3N2 or influenza B components in LAIV even in children 18, 19 . Interestingly, when we considered the influenza-specific IgA data generated by HA microarray, three subjects showed a significant response to H1 HA and three subjects to H3 HA (2 subjects showed a ≥2-fold increase to both H1pdm09 and H3 HA). It is difficult to conclude from these data whether the ELISA or microarray data reflect a more biologically relevant result and further studies are required to validate the HA microarray assay in particular.
Given the recent varying effectiveness [20] [21] [22] and efficacy 23, 24 of both the Ann Arbor and Leningrad backbone LAIV preparations, there is an urgent need to conduct studies which incorporate reliable mucosal immunogenicity endpoints following LAIV. Studies of natural influenza infection, as well as human influenza challenge models can also enhance our knowledge of anti-influenza mucosal immunity. We provide novel data on both sampling methods and IgA assays for use in such studies. Supplementary Table 1 . The H1-and H3-specific IgA response to LAIV measured by ELISA and protein microarray. Response is expressed as fold-change from day 0 (baseline) to day 28 after normalization by total IgA quantity in the sample. Shown are data generated from flocked swabs. Responses with ≥ 2-fold increase in normalized IgA following LAIV are highlighted. # (Specific IgA at day 28 (ng/µL in ELISA or fluorescence units in microarray)/total IgA on day 28 (µg/ml) (Specific IgA at day 0 (ng/uL in ELISA or fluorescence units in microarray)/total IgA on day 0 (µg/ml) † Unable to measure fold-change as no detectable H3-specific IgA at baseline. † † Unable to calculate fold-change as background corrected fluorescence value negative at baseline.
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